Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

Testosterone patch scripts ‘often outside guidelines’

By Lilian Anekwe

Fewer than 30% of women using a testosterone patch for hypoactive sexual desire disorder (HSDD) are being prescribed it within guidelines, drug safety researchers warn.

Researchers surveyed GPs who had issued prescriptions for the Intrinsa transdermal testosterone patches to 756 patients from March 2007.

Intrinsa is indicated for use in HSDD in women but only in those who have undergone bilateral oophorectomy and hysterectomy and are on oestrogen therapy. The analysis found that 580 patients were prescribed it for HSDD. But only 364 were

reported to have had both a hysterectomy and bilateral ooph-orectomy. Some 222 patients were not on oestrogen therapy and only 219 prescriptions were in accordance with manufacturer's recommendations.

Study author Dr Vicki Osborne, research fellow at the Drug Safety Research Unit in Southampton, said: ‘Some clinicians are prescribing this product outside the recommended terms of the licence.'

Drug Safety 2010;33:213-21

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say